| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -42,335 | -29,447 |
| Stock-based compensation | 7,011 | 3,035 |
| Non-cash operating lease expense | 144 | 88 |
| Accretion of discounts on marketable securities, net | 1,763 | 1,240 |
| Depreciation and amortization expense | 67 | 38 |
| In-process research and development, related party | 0 | 0 |
| Unrealized foreign currency transaction (gain) loss | -23 | -24 |
| Prepaid expenses and other current assets | 110 | -1,272 |
| Other long-term assets | 1,514 | 1,352 |
| Accounts payable | -228 | 165 |
| Accounts payable and accrued liabilities, related party-Related Party | 0 | 0 |
| Accrued expenses and other current liabilities | 152 | 944 |
| Operating lease liabilities | -168 | -109 |
| Long-term liabilities | 0 | 0 |
| Net cash used in operating activities | -38,721 | -26,582 |
| Purchases of property and equipment | 186 | 77 |
| Purchases of marketable securities | 103,082 | 79,370 |
| Maturities of marketable securities | 80,563 | 41,482 |
| Issuance of promissory loan in connection with asset acquisition | 0 | 0 |
| Cash paid in connection with asset acquisition, net of cash received | 0 | 0 |
| Net cash used in investing activities | -22,705 | -37,965 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock in private placement, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 |
| Net change in cash and cash equivalents | -61,426 | -64,547 |
| Cash and cash equivalents at beginning of period | 87,229 | - |
| Cash and cash equivalents at end of period | 25,803 | - |
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)